Invokana Sales Figure Witness a Dip
Invokana Sales Figure Witness a Dip
Introduction
According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.
Comments
Latest News
First Federal Bellwether Trial Set in Strattice Mesh Case
Categories: Hernia Mesh
Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…
Tepezza Hearing Loss Trial Set for June 2026
Categories: Tepezza
The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.
This decision comes as attorneys…
FDA Moves to Restrict Dangerous 7-OH Opioid Products
Categories: Opioids
In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…